Table of contents
- Trial overview
- Who participated
- What was studied
- Phase and study design
- Main endpoint
- What the results mean for patients
Trial overview
The available clinical trial studied HUMAN PAPILLOMAVIRUS TYPE 16 L1 PROTEIN ADJUVANTED BY AS04 ADSORBED ON ALUMINIUM HYDROXIDE, HYDRATED PRODUCED ON BACULOVIRUS HI-5 RIX4446 CELLS, TRICHOPLUSIA NI. DERIVED in the context of HPV infection prevention among healthy participants.[1] The trial was authorised and planned to include 730 people.[1]
Who participated
The target group was men who have sex with men (MSM) aged 19 to 26 years who visited the Sexual Health Clinic in Amsterdam.[1] This makes the study very specific, because it focused on a young adult group with a defined care setting.[1]
The trial description also shows that the study compared vaccinated and unvaccinated MSM attending the clinic.[1] This kind of comparison helps researchers see whether vaccination is linked to fewer infections in real-life clinic visitors.[1]
What was studied
The study was designed to assess the direct effectiveness of vaccination with the bivalent HPV vaccine, also named Cervarix, against anal HPV-16 and HPV-18 infections.[1] In simple terms, the researchers wanted to know whether vaccinated people had less HPV detected in the anal area than unvaccinated people.[1]
The intervention listed in the trial was a drug described as Cervarix suspension for injection in a multidose container, given by intramuscular injection.[1] The source data also describes the study as interventional, meaning the researchers were studying a vaccine given as part of the trial.[1]
Phase and study design
This was a Phase 3 trial.[1] Phase 3 studies usually look at how well a treatment works in a larger group of people after earlier testing has already taken place.[1]
Even though the brief summary calls it a study of vaccine effectiveness, the trial record also labels it as interventional.[1] The design involved comparing two groups: vaccinated participants and unvaccinated participants.[1]
Main endpoint
The main outcome was HPV-16 and HPV-18 DNA positivity.[1] This means researchers measured whether the genetic material of HPV types 16 and 18 was found in samples, which shows current infection at the time of testing.[1]
The primary outcome specifically mentions comparing anal HPV-16/18 prevalence between vaccinated and unvaccinated MSM attending the sexual health center.[1] Prevalence means how common the infection was in the study group at the time of assessment.[1]
What the results mean for patients
For patients, this trial is important because it focuses on whether vaccination can lower the chance of anal HPV-16 and HPV-18 infection in a real clinic population.[1] The study does not describe long-term treatment of disease; instead, it looks at prevention in a defined group of young adult MSM.[1]
The trial information provided here is limited to one study, so the main message is that the research is centered on vaccine effectiveness, not on symptom treatment.[1] The key measured result is whether HPV DNA is present or not in anal samples.[1]
